Dosologic: a precision dosing software optimising chemotherapy for children.

** 维辛塔是谁 **一家个性化医药公司，通过快速患者监测提供数据指导的精确给药。**我们在帮助谁？全球每年有40万儿童被诊断患有癌症 **挑战是什么？**选择最佳化疗剂量。许多因素（脂肪分布/器官功能/酶可用性等）影响药物的代谢和清除。这些差异在儿童中被夸大了，因为他们的解剖结构发育迅速。这在实践中意味着什么？**给予相同剂量的两个人可能有非常不同的“药物暴露”，即血液中药物的浓度和停留时间。这是哪种药物的问题？**用于治疗严重疾病的药物，包括化疗药物。如果药物暴露太低，癌症将继续增长。然而，如果药物暴露过高，患者可能会遭受毒副作用。临床医生是如何处理的？**到目前为止，患者的体重或表面积用于确定化疗剂量。这并不能动态地捕捉单个患者的整个临床复杂性。**如何改进？**提供支持化疗剂量调整至“目标药物暴露”的证据。通过测量随时间推移采集的血液样本中的药物浓度，我们可以预测达到最佳药物暴露的正确剂量。这很难吗？**每次剂量调整都需要药理学专业知识和临床数据处理。然而，通过智能软件补充护理点监测设备，这种个性化水平可能成为所有人的护理标准。软件会做什么？**它将使用浓度数据为每个患者建立一个独特的“药代动力学”模型。用户友好的床边界面将支持临床医生每次提供最佳剂量，使个性化的儿童癌症治疗更加安全，有效和精确。我们可以交付吗？**我们的团队包括世界领先的工程师、药理学家、企业家和儿科肿瘤学家。国家卫生研究所的资金已经支持了我们药物监测硬件的开发。Dosologic现在开发了一款精确定量软件，以创建“剂量-测量-学习”精确定量循环。**我什么时候能看到这一点？**我们的创新管道将需要严格的测试和监管批准，并于2024年进入临床环境。还有谁受益于个性化给药？**由于临床试验代表性不足而需要定制治疗的任何患者群体（老年人、女性、少数民族、罕见病患者）。医疗保健提供者、家庭和更广泛的经济都受益于更少的毒性事件和癌症儿童生活质量的提高。

**Who is Vesynta?**A personalised medicine company that delivers data-guided precision dosing via rapid patient monitoring.**Who are we helping?**The 400,000 children diagnosed with cancer globally each year.**What's the challenge?**Choosing the optimal chemotherapy dose. Many factors (fat distribution/organ function/enzyme availability, etc.) affect how drugs are metabolised and cleared from our bodies. These differences are exaggerated in children due to their rapidly developing anatomy.**What does this mean in practice?**Two people given the same dose may have very different "drug-exposures" i.e. concentration of a drug in the blood and the length of time it stays there.**Which drugs is this a problem for?**Drugs used to treat critical illnesses, including chemotherapeutics. If drug exposure is too low, cancer will continue to grow. Whereas, if drug exposure is too high the patient may suffer from toxic side effects.**How have clinicians dealt with this?**Until now, the patient's weight or surface area is used to determine the chemotherapy dose. This does not dynamically capture the entire clinical complexity of an individual patient.**How could we improve?**Provide access to evidence that supports chemotherapy dose adjustments towards a "target drug exposure". By measuring drug concentrations from blood samples taken over time, we can predict the right dose to achieve the optimum drug exposure.**Is this difficult?**Each dose adjustment requires pharmacology expertise and processing of clinical data. However, with intelligent software that complements a point-of-care monitoring device, this level of personalisation could become standard of care for all.**What will the software do?**It will use concentration data to build a unique "pharmacokinetic" model for each patient. A user-friendly bedside interface will support clinicians to deliver the optimal dose every time, making personalised childhood cancer treatment more safe, effective and precise.**Can we deliver?**Our team includes world-leading engineers, pharmacologists, entrepreneurs, and paediatric oncologists. NIHR-funding already supports development of our drug monitoring hardware. Dosologic now develops a precision dosing software to create a "Dose-Measure-Learn" precision dosing loop.**When will I see this in action?**Our innovation pipeline will require rigorous testing and regulatory approval, entering the clinical setting in 2024\.**Who else benefits from personalised dosing?**Any patient group that requires tailored treatment due to clinical trial under-representation (elderly, women, ethnic minorities, patients with rare disease). Healthcare providers, families and the wider economy all benefit from fewer toxic events and enhanced quality of life for children with cancer.